{"pmid":32343410,"title":"COVID-19 in Tuberculosis patients: a report of three cases.","text":["COVID-19 in Tuberculosis patients: a report of three cases.","The clinical features and treatment of pulmonary tuberculosis patients with COVID-19 is unclear and understudied. Here, three pulmonary tuberculosis patients with COVID-19 infection were prospectively followed from hospital admission to discharge. We provide information and experience with treatment of pulmonary tuberculosis cases with confirmed COVID-19 infection. This article is protected by copyright. All rights reserved.","J Med Virol","He, Guiqing","Wu, Jing","Shi, Jichan","Dai, Jianyi","Gamber, Michelle","Jiang, Xiangao","Sun, Wenjie","Cai, Jing","32343410"],"abstract":["The clinical features and treatment of pulmonary tuberculosis patients with COVID-19 is unclear and understudied. Here, three pulmonary tuberculosis patients with COVID-19 infection were prospectively followed from hospital admission to discharge. We provide information and experience with treatment of pulmonary tuberculosis cases with confirmed COVID-19 infection. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["He, Guiqing","Wu, Jing","Shi, Jichan","Dai, Jianyi","Gamber, Michelle","Jiang, Xiangao","Sun, Wenjie","Cai, Jing"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343410","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25943","keywords":["coronavirus","immune responses","infection"],"topics":["Case Report"],"weight":1,"_version_":1665351883898748928,"score":8.574329,"similar":[{"pmid":32308221,"title":"Imported Infections in Rural Mid-West United States - A Report from a Tertiary Care Center.","text":["Imported Infections in Rural Mid-West United States - A Report from a Tertiary Care Center.","Background: There is lack of specific data on imported infections in the mid-west United States (U.S.). Methods: Retrospective data on demographic and geographic data of imported infections seen by the infectious diseases clinics and consultation service from 2001-2018 was collected. Results: Of the 64 infections, tuberculosis(TB) was most common [20(31.3%); pulmonary(11,55%), lymphadenopathy(8,40%), gastrointestinal(4,20%), disseminated(2,10%), and 1(5%) each of genitourinary and vertebral spine infection, 4 Human immune-deficiency virus infection and 1 echinococcosis)] followed by malaria(11,17.2%). Other infections: Cysticercosis [7,10.9%], giardiasis (4,6.3%), 3 each (4.7%) Human T-lymphotrophic Virus infection and schistosomiasis, 2 each (3.1%) leprosy, strongyloidiasis, and typhoid fever, one each (1.6%) of ascariasis, brucellosis, Chagas disease, Chikungunya virus, hepatitis A virus, echinococcosis, Japanese encephalitis virus, loiasis, paratyphoid fever, Q fever, and unspecified parasitosis. Geographic origins: Africa(26,40.6%), Asia(16,25%), Central America(11,17.2%), Europe(2,3.1%), Oceania(2,3.1%), South America(2,3.1%), and Unknown(5). More cases were seen after 2015. Conclusions: With increasing tourism, it is important to educate rural mid-west healthcare professionals on travel medicine. The current COVID-19 pandemic illustrates the importance of this type of education and data accumulation now and in the future.","Mo Med","Meyer, Amy","Regunath, Hariharan","Rojas-Moreno, Christian","Salzer, William","Christensen, Gordon","32308221"],"abstract":["Background: There is lack of specific data on imported infections in the mid-west United States (U.S.). Methods: Retrospective data on demographic and geographic data of imported infections seen by the infectious diseases clinics and consultation service from 2001-2018 was collected. Results: Of the 64 infections, tuberculosis(TB) was most common [20(31.3%); pulmonary(11,55%), lymphadenopathy(8,40%), gastrointestinal(4,20%), disseminated(2,10%), and 1(5%) each of genitourinary and vertebral spine infection, 4 Human immune-deficiency virus infection and 1 echinococcosis)] followed by malaria(11,17.2%). Other infections: Cysticercosis [7,10.9%], giardiasis (4,6.3%), 3 each (4.7%) Human T-lymphotrophic Virus infection and schistosomiasis, 2 each (3.1%) leprosy, strongyloidiasis, and typhoid fever, one each (1.6%) of ascariasis, brucellosis, Chagas disease, Chikungunya virus, hepatitis A virus, echinococcosis, Japanese encephalitis virus, loiasis, paratyphoid fever, Q fever, and unspecified parasitosis. Geographic origins: Africa(26,40.6%), Asia(16,25%), Central America(11,17.2%), Europe(2,3.1%), Oceania(2,3.1%), South America(2,3.1%), and Unknown(5). More cases were seen after 2015. Conclusions: With increasing tourism, it is important to educate rural mid-west healthcare professionals on travel medicine. The current COVID-19 pandemic illustrates the importance of this type of education and data accumulation now and in the future."],"journal":"Mo Med","authors":["Meyer, Amy","Regunath, Hariharan","Rojas-Moreno, Christian","Salzer, William","Christensen, Gordon"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32308221","week":"202017|Apr 20 - Apr 26","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States","USA","Japanese"],"countries":["Japan","United States"],"countries_codes":["JPN|Japan","USA|United States"],"_version_":1664632501554905088,"score":174.33578},{"pmid":32314799,"title":"Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","text":["Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R","32314799"],"abstract":["Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314799","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25907","keywords":["coronavirus","disease control","immune responses","immunodulators","interleukin","virus classification"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664714520108466176,"score":167.19896},{"pmid":32190904,"title":"Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients.","text":["Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients.","At present, Coronavirus Disease 2019 (COVID-19) is rampaging around the world. However, asymptomatic carriers intensified the difficulty of prevention and management. Here we reported the screening, clinical feathers, and treatment process of a family cluster involving three COVID-19 patients. The discovery of the first asymptomatic carrier in this family cluster depends on the repeated and comprehensive epidemiological investigation by disease control experts. In addition, the combination of multiple detection methods can help clinicians find asymptomatic carriers as early as possible. In conclusion, the prevention and control experience of this family cluster showed that comprehensive rigorous epidemiological investigation and combination of multiple detection methods were of great value for the detection of hidden asymptomatic carriers. This article is protected by copyright. All rights reserved.","J Med Virol","Lu, Shubiao","Lin, Jinsong","Zhang, Zhiqiao","Xiao, Liping","Jiang, Zhijian","Chen, Jia","Hu, Chongjing","Luo, Shi","32190904"],"abstract":["At present, Coronavirus Disease 2019 (COVID-19) is rampaging around the world. However, asymptomatic carriers intensified the difficulty of prevention and management. Here we reported the screening, clinical feathers, and treatment process of a family cluster involving three COVID-19 patients. The discovery of the first asymptomatic carrier in this family cluster depends on the repeated and comprehensive epidemiological investigation by disease control experts. In addition, the combination of multiple detection methods can help clinicians find asymptomatic carriers as early as possible. In conclusion, the prevention and control experience of this family cluster showed that comprehensive rigorous epidemiological investigation and combination of multiple detection methods were of great value for the detection of hidden asymptomatic carriers. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lu, Shubiao","Lin, Jinsong","Zhang, Zhiqiao","Xiao, Liping","Jiang, Zhijian","Chen, Jia","Hu, Chongjing","Luo, Shi"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32190904","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25776","keywords":["covid-19","family cluster","incubation period"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664640874518151168,"score":148.51227},{"pmid":32271603,"title":"Dynamic Chest CT Evaluation in Three Cases of 2019 Novel Coronavirus Pneumonia.","text":["Dynamic Chest CT Evaluation in Three Cases of 2019 Novel Coronavirus Pneumonia.","A recent outbreak of pneumonia in Wuhan, China, was caused by the 2019 novel coronavirus (2019-nCoV). There have been some reports of imaging findings regarding the disease's characteristic features. Here, we report three cases of coronavirus disease 2019 (COVID-19) with dynamic pulmonary CT evaluation. The CT scan showed multiple regions of ground-glass opacities and patchy consolidation in COVID-19 patients and the CT scan was useful in tracking the progression or regression of COVID-19.","Arch Iran Med","Chen, Xing","Liu, Shuying","Zhang, Chunyi","Pu, Guimei","Sun, Jian","Shen, Juxin","Chen, Yefeng","32271603"],"abstract":["A recent outbreak of pneumonia in Wuhan, China, was caused by the 2019 novel coronavirus (2019-nCoV). There have been some reports of imaging findings regarding the disease's characteristic features. Here, we report three cases of coronavirus disease 2019 (COVID-19) with dynamic pulmonary CT evaluation. The CT scan showed multiple regions of ground-glass opacities and patchy consolidation in COVID-19 patients and the CT scan was useful in tracking the progression or regression of COVID-19."],"journal":"Arch Iran Med","authors":["Chen, Xing","Liu, Shuying","Zhang, Chunyi","Pu, Guimei","Sun, Jian","Shen, Juxin","Chen, Yefeng"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271603","week":"202015|Apr 06 - Apr 12","doi":"10.34172/aim.2020.11","keywords":["2019-novel coronavirus pneumonia","chest computed tomography","clinical characteristics","coronavirus disease 2019","dynamic evaluation"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664637315548446720,"score":139.2164},{"pmid":32222992,"title":"Detectable SARS-CoV-2 Viral RNA in Feces of Three Children during Recovery Period of COVID-19 Pneumonia.","text":["Detectable SARS-CoV-2 Viral RNA in Feces of Three Children during Recovery Period of COVID-19 Pneumonia.","Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. According to the World Health Organization (WHO) statement on March 13, 2020, there had been over 132,500 confirmed cases globally. Nevertheless, the case reports of children are rare, which result in the lack of evidence for preventing and controlling of children's infection. Here, we report 3 cases of SARS-CoV-2 infected children diagnosed from February 3 to February 17, 2020 in Tianjin, China. All of these three cases experienced mild illness and recovered soon after treatment, with the nucleic acid of throat swab turning negative within 14, 11, 7 days after diagnosis respectively. However, after been discharged, all the three cases were tested SARS-CoV-2 positive in the stool samples within 10 days, in spite of their remained negative nucleic acid in throat swab specimens. Therefore, it is necessary to be aware of the possibility of fecal-oral transmission of SARS-CoV-2 infection, especially for children cases. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Tongqiang","Cui, Xiaojian","Zhao, Xue","Wang, Jinhu","Zheng, Jiafeng","Zheng, Guifen","Guo, Wei","Cai, Chunquan","He, Sijia","Xu, Yongsheng","32222992"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. According to the World Health Organization (WHO) statement on March 13, 2020, there had been over 132,500 confirmed cases globally. Nevertheless, the case reports of children are rare, which result in the lack of evidence for preventing and controlling of children's infection. Here, we report 3 cases of SARS-CoV-2 infected children diagnosed from February 3 to February 17, 2020 in Tianjin, China. All of these three cases experienced mild illness and recovered soon after treatment, with the nucleic acid of throat swab turning negative within 14, 11, 7 days after diagnosis respectively. However, after been discharged, all the three cases were tested SARS-CoV-2 positive in the stool samples within 10 days, in spite of their remained negative nucleic acid in throat swab specimens. Therefore, it is necessary to be aware of the possibility of fecal-oral transmission of SARS-CoV-2 infection, especially for children cases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Tongqiang","Cui, Xiaojian","Zhao, Xue","Wang, Jinhu","Zheng, Jiafeng","Zheng, Guifen","Guo, Wei","Cai, Chunquan","He, Sijia","Xu, Yongsheng"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222992","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25795","keywords":["COVID-19","Children","Clinical characteristics","SARS-CoV-2"],"source":"PubMed","locations":["Feces","Pneumonia","Wuhan","China","Tianjin"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1663352135189790724,"score":138.07787}]}